COLOPHON -- PANEL No.8
About TB-500 Meds.
What this project is, what it is not, and why a comic page is the right form for a research record built from quotable facts.
What TB-500 Meds is
TB-500 Meds is an independent editorial project that publishes summaries of the peer-reviewed research literature on TB-500 and its parent protein, thymosin beta-4. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The site exists because the public record on this compound is unusually muddled — and unusually salvageable. "TB-500" is a short, quotable peptide with a deep literature attached to a different, larger molecule. Sorting those apart, panel by panel, is most of the value we can add.
What the name does and does not claim
The "Meds" in the name is editorial framing, not a description of services. This project does not dispense, prescribe, compound, or supply anything. It does not offer treatment, consultation, or prescription services, and it has no doctors, pharmacists, or clinical team behind it. "Meds" signals the register we read the literature in — the regulatory and access questions a medicinal substance raises, including the FDA 503A status covered on TB-500 legal status and FDA 503A category — not a counter you can buy from.
We also keep a hard line the source material keeps blurring: TB-500 the heptapeptide is not thymosin beta-4 the protein, and we flag which one a finding used every time it matters.
How we work
Every quantitative claim on this site — every percentage, dose, molecular weight, and trial figure — maps to a numbered citation on the references page, drawn from PubMed-indexed journals and, for regulatory facts, directly from FDA.gov. We describe what was administered to which species at which dose by which route. We do not recommend doses for humans, and we do not present community protocols as validated.
The comic-page form is a deliberate fit. A research record made of discrete, checkable facts — +61% re-epithelialization, 2/12/18 mg/kg, ~889 Da versus ~4963 Da — reads well as panels you cannot skim past, with the recurring editor's note doing the honest work of saying, again and again, which molecule the data actually came from.